International Medical School, University of Milan

Implantica Announces Completion of First RefluxStop™ procedures by the President of the European Foregut Society

Retrieved on: 
Thursday, June 8, 2023
Surgeon, University, Gastroesophageal reflux disease, Operating, Patient, EFS, International Medical School, University of Milan, Pharmaceutical industry, Dentistry, AIRES

He is the current President of the European Foregut Society (EFS) and also the Italian Association of Esophageal Research (AIRES).

Key Points: 
  • He is the current President of the European Foregut Society (EFS) and also the Italian Association of Esophageal Research (AIRES).
  • It is important that surgeons are offering disruptive treatment solutions with such encouraging early outcomes," says Prof. Bonavina.
  • "Implantica is thrilled and proud to partner with Prof. Bonavina, one of the world's most accomplished and respected anti-reflux experts.
  • We look forward to continuing and further strengthening our collaboration with Prof. Bonavina," says Dr. Peter Forsell, CEO of Implantica.

Curaleaf International to Present Positive Clinical and Pre-Clincial Research

Retrieved on: 
Thursday, October 20, 2022
Research, Finance, Cannabis, Clinical Trials, Professional Services, Alternative Medicine, Health, Science, Natural Resources, News, International, Dyspareunia, Imperial College London, University of Insubria, Migraine, Cannabis, Inflammation, Growth, Conference, Woman, Science, Curaleaf, Brain-derived neurotrophic factor, Genital wart, Patient, Grassroots, Lists of diseases, Research, VBD, BDNF, CNSX, International Medical School, University of Milan, University, Sex, Trial of the century, Company, Vulval vestibule, MPFC, ROS, CSE, Pain, Canadian Securities Exchange, Karger Publishers, OTCQX, ECS, Plasma, PMN, Brain, Reactive oxygen species, Title, Pharmaceutical industry, Drug, Audit, CBD, Cannabinoid, Select, Cannabidiol

MD., F. Vicariotto, Prof. MD and Barbara Pacchetti, Chief Scientific Officer at Curaleaf International.

Key Points: 
  • MD., F. Vicariotto, Prof. MD and Barbara Pacchetti, Chief Scientific Officer at Curaleaf International.
  • For further information on the preclinical research to be presented, please see the footnote at the end of this announcement.
  • Curaleaf International (formerly EMMAC Life Sciences Group) is Europes largest vertically integrated cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production.
  • Curaleaf International assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.